GLP1R and cancer: Research about dipeptidyl peptidase-4 (DPP-4) inhibitors, which function via a similar mechanism as GLP-1 receptor agonists, failed to verify an association between the use of these drugs and an increased risk of site-specific cancer, and this was attributed to the small number of studies for each cancer type and their relatively short duration [50].